For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

Tan France is using his experience in fashion way beyond styling. Now, the Queer Eye staple is partnering with Lilly, the makers of Zepbound, for the Changing the Thread Collection™, the first ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks.

The global health organization now officially backs drugs like Wegovy for obesity management. But it might be more symbolic ...